IP Library Granted Patent US 12691101
Granted Patent B2
US 12691101 · App. 17/601,114 · Granted Jul 28, 2026

Compound and method for preventing or treating of respiratory diseases comprising the same as an active ingredient

Inventors: Jae Young Choi (Seoul, KR); Gyoonhee Han (Seoul, KR); Wan Namkung (Incheon, KR); Sung Ha Park (Seoul, KR); Moo Suk Park (Seoul, KR)
Assignee: YONSEI UNIVERSITY, UNIVERSITY—INDUSTRY FOUNDATION (UIF)
A61K31/422A61K9/0056A61K31/341A61K31/381A61K31/40A61K31/415A61K31/421A61K31/426A61K31/427A61K31/4439A61K31/454A61K31/4709A61K31/519A61P11/06C07D207/337C07D209/20C07D231/12C07D263/42C07D277/30C07D307/54C07D333/24C07D333/60C07D413/04C07D413/06C07D413/10C07D413/12C07D413/14C07D417/06C07D495/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12691101
App. No.
17/601,114
Filed
Oct 4, 2021
Granted
Jul 28, 2026
Kind
B2
Art Unit
1621
USPC
514/260.1
Abstract

The present invention relates to a novel compound, and a composition for preventing or treating of respiratory disease comprising the novel compound, E- or Z-isomer thereof, optical isomer thereof, a mixture of two isomers thereof, precursor thereof, pharmaceutically acceptable salt thereof or solvate thereof as an active ingredient.

Claims (28)

1 . A compound selected from the group consisting of the following compounds listed in Table 1, an E- or Z-isomer thereof, an optical isomer thereof, a mixture of two isomers selected from the E-isomer, Z-isomer and optical isomer thereof, a pharmaceutically acceptable salt thereof, or a solvate thereof:

TABLE 1

Compound

Structural

No.

Formula

F2

F8

F10

F12

F19

F20

F26

F143

F148

G3

G7

G8

G22

G26

G28

G29

G35

G37

G40

2 . A composition comprising the compound, E- or Z-isomer thereof, optical isomer thereof, a mixture of two isomers selected from the E-isomer, Z-isomer, and optical isomer thereof, pharmaceutically acceptable salt thereof or solvate thereof according to claim 1 as an active ingredient.

3 . The composition according to claim 2 , further comprising a pharmaceutically acceptable carrier.

4 . The composition according to claim 2 , further comprising another pharmaceutical ingredient.